1
|
Moretto R, Germani MM, Borelli B, Conca V, Rossini D, Boraschi P, Donati F, Urbani L, Lonardi S, Bergamo F, Cerma K, Ramondo G, D'Amico FE, Salvatore L, Valente G, Barbaro B, Giuliante F, Di Maio M, Masi G, Cremolini C. Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience. ESMO Open 2024; 9:102991. [PMID: 38631269 PMCID: PMC11027482 DOI: 10.1016/j.esmoop.2024.102991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2024] [Revised: 03/09/2024] [Accepted: 03/11/2024] [Indexed: 04/19/2024] Open
Abstract
BACKGROUND Advances in surgical techniques and systemic treatments have increased the likelihood of achieving radical surgery and long-term survival in metastatic colorectal cancer (mCRC) patients with initially unresectable colorectal liver metastases (CRLMs). Nonetheless, roughly half of the patients resected after an upfront systemic therapy experience disease relapse within 6 months from surgery, thus leading to the question whether surgery is actually beneficial for these patients. MATERIALS AND METHODS A real-world dataset of mCRC patients with initially unresectable liver-limited disease treated with conversion chemotherapy followed by radical resection of CRLMs at three high-volume Italian institutions was retrospectively assessed with the aim of investigating the association of baseline and pre-surgical clinical, radiological and molecular factors with the risk of relapse within 6 or 12 months from surgery. RESULTS Overall, 268 patients were included in the analysis and 207 (77%) experienced recurrence. Ninety-six (46%) of them had disease relapse within 6 months after CRLM resection and in spite of several variables associated with early recurrence at univariate analyses, only primary tumour resection at diagnosis [odds ratio (OR) 0.53, 95% confidence interval (CI) 0.32-0.89, P = 0.02] remained significant in the multivariable model. Among patients with resected primary tumours, pN+ stage was associated with higher risk of disease relapse within 6 months (OR 3.02, 95% CI 1.23-7.41, P = 0.02). One hundred and forty-nine patients (72%) had disease relapse within 12 months after CRLMs resection but none of the analysed variables was independently associated with outcome. CONCLUSIONS Clinical, radiological and molecular factors assessed before and after conversion chemotherapy do not reliably predict early recurrence after secondary resection of initially unresectable CRLMs. While novel markers are needed to optimize the cost/efficacy balance of surgical procedures, CRLM resection should be offered as soon as metastases become resectable during first-line chemotherapy to all patients eligible for surgery.
Collapse
Affiliation(s)
- R Moretto
- Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa
| | - M M Germani
- Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa
| | - B Borelli
- Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa
| | - V Conca
- Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa
| | - D Rossini
- Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Pisa
| | - P Boraschi
- Department of Diagnostic and Interventional Radiology, and Nuclear Medicine, Azienda Ospedaliero-Universitaria Pisana, Pisa
| | - F Donati
- Department of Diagnostic and Interventional Radiology, and Nuclear Medicine, Azienda Ospedaliero-Universitaria Pisana, Pisa
| | - L Urbani
- General Surgery, Azienda Ospedaliero-Universitaria Pisana, Pisa
| | - S Lonardi
- Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua
| | - F Bergamo
- Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua
| | - K Cerma
- Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua
| | - G Ramondo
- Radiology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua
| | - F E D'Amico
- General Surgery 2, Department of Surgical Oncological and Gastroenterological Sciences (DISCOG), University of Padua, Padua
| | - L Salvatore
- Medical Oncology Unit, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome; Medical Oncology Unit, Università Cattolica del Sacro Cuore, Rome
| | - G Valente
- Medical Oncology Unit, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome; Medical Oncology Unit, Università Cattolica del Sacro Cuore, Rome
| | - B Barbaro
- Diagnostic and General Interventional Radiology, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome
| | - F Giuliante
- General and Hepatobiliary Surgery, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome
| | - M Di Maio
- Department of Oncology, Università degli Studi di Torino, Turin, Italy
| | - G Masi
- Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa
| | - C Cremolini
- Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa.
| |
Collapse
|
2
|
Germani MM, Vetere G, Santamaria F, Intini R, Ghelardi F, Bensi M, Boccaccino A, Minelli A, Carullo M, Ciracì P, Passardi A, Santucci S, Giampieri R, Persano M, Fenocchio E, Puccini A, Lonardi S, Pietrantonio F, Salvatore L, Cremolini C. Treatment of patients with BRAF V600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset. ESMO Open 2024; 9:102996. [PMID: 38613911 PMCID: PMC11024565 DOI: 10.1016/j.esmoop.2024.102996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2024] [Revised: 03/13/2024] [Accepted: 03/14/2024] [Indexed: 04/15/2024] Open
Abstract
BACKGROUND Targeted therapy (TT) with encorafenib and cetuximab is the current standard for patients with BRAFV600E-mutated metastatic colorectal cancer (mCRC) who received one or more prior systemic treatments. However, the median progression-free survival (mPFS) is ∼4 months, and little is known about the possibility of administering subsequent therapies, their efficacy, and clinicopathological determinants of outcome. METHODS A real-world dataset including patients with BRAFV600E-mutated mCRC treated with TT at 21 Italian centers was retrospectively interrogated. We assessed treatments after progression, attrition rates, and outcomes. RESULTS Of the 179 patients included, 85 (47%), 32 (18%), and 7 (4%) received one, two, or three lines of treatment after TT, respectively. Those receiving TT in the second line were more likely to receive at least one subsequent therapy (53%), as compared with those treated with TT in the third line or beyond (30%; P < 0.0001), and achieved longer postprogression survival (PPS), also in a multivariate model (P = 0.0001). Among 62 patients with proficient mismatch repair/microsatellite stable (pMMR/MSS) tumors receiving one or more lines of treatment after second-line TT, combinatory chemotherapy ± anti-vascular endothelial growth factor (anti-VEGF) was associated with longer PFS and PPS as compared with trifluridine-tipiracil or regorafenib (mPFS: 2.6 versus 2.0 months, P = 0.07; PPS: 6.5 versus 4.4 months, P = 0.04). CONCLUSIONS Our real-world data suggest that TT should be initiated as soon as possible after the failure of first-line treatment in BRAFV600E-mutated mCRC. Among patients with pMMR/MSS tumors, combinatory chemotherapy ± anti-VEGF appears the preferred treatment choice after TT failure.
Collapse
Affiliation(s)
- M M Germani
- Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa
| | - G Vetere
- Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa
| | - F Santamaria
- Department of Experimental Medicine, Sapienza University of Rome, Rome
| | - R Intini
- Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua
| | - F Ghelardi
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - M Bensi
- Medical Oncology Unit, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome; Medical Oncology Unit, Università Cattolica del Sacro Cuore, Rome
| | - A Boccaccino
- Oncology Unit, Ravenna Hospital, AUSL Romagna, Ravenna
| | - A Minelli
- Department of Medical Oncology, University Campus Bio-Medico, Rome
| | - M Carullo
- Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa
| | - P Ciracì
- Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa
| | - A Passardi
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola
| | - S Santucci
- Oncology Unit, Ravenna Hospital, AUSL Romagna, Ravenna
| | - R Giampieri
- Oncologia Clinica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Torrette di Ancona, Ancona; Oncologia Clinica, Azienda Ospedaliero-Universitaria delle Marche, Ancona
| | - M Persano
- Medical Oncology, University Hospital of Cagliari, Cagliari; Medical Oncology, University of Cagliari, Cagliari
| | - E Fenocchio
- Department of Medical Oncology, University of Turin Medical School, Candiolo Cancer Institute, FPO, IRCCS, Candiolo, Turin
| | - A Puccini
- Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Rozzano, Milan, Italy
| | - S Lonardi
- Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua
| | - F Pietrantonio
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - L Salvatore
- Medical Oncology Unit, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome; Medical Oncology Unit, Università Cattolica del Sacro Cuore, Rome
| | - C Cremolini
- Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa.
| |
Collapse
|
3
|
Palazzo A, Ciccarese C, Iacovelli R, Cannizzaro MC, Stefani A, Salvatore L, Bria E, Tortora G. Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis. ESMO Open 2023; 8:101154. [PMID: 36893518 PMCID: PMC10163166 DOI: 10.1016/j.esmoop.2023.101154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Revised: 01/27/2023] [Accepted: 01/31/2023] [Indexed: 03/09/2023] Open
Abstract
BACKGROUND Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) provided significant antitumor activity in various tumors, mainly carrying deleterious mutations of BRCA1/BRCA2 genes. Only few data are available regarding the cardiac and vascular safety profile of this drug class. We carried out a meta-analysis for assessing the incidence and relative risk (RR) of major adverse cardiovascular events (MACEs), hypertension, and thromboembolic events in patients with solid tumors treated with PARPi-based therapy. METHODS Prospective studies were identified by searching the Medline/PubMed, Cochrane Library, and ASCO Meeting abstracts. Data extraction was conducted according to the Preferred Reporting Items for Systematic review and Meta-Analyses (PRISMA) statement. Combined odds ratios (ORs), RRs, and 95% confidence intervals (CIs) were calculated using fixed- or random-effects methods, depending on studies heterogeneity. RevMan software for meta-analysis (v.5.2.3) was used to carry out statistical analyses. RESULTS Thirty-two studies were selected for the final analysis. The incidence of PARPi-related MACEs of any and high grade was 5.0% and 0.9%, respectively, compared with 3.6% and 0.9% in the control arms, corresponding to a significant increased risk of MACEs of any grade (Peto OR 1.62; P = 0.0009) but not of high grade (P = 0.49). The incidence of hypertension of any grade and high grade was 17.5% and 6.0% with PARPi, respectively, compared with 12.6% and 4.4% in the controls. Treatment with PARPi significantly increased the risk of hypertension of any grade (random-effects, RR = 1.53; P = 0.03) but not of high grade (random-effects, RR = 1.47; P = 0.09) compared with controls. Finally, PARPi-based therapies significantly increased the risk of thromboembolic events of any grade (Peto OR = 1.49, P = 0.004) and not of high grade (Peto OR = 1.31; P = 0.13) compared with controls. CONCLUSIONS PARPi-based therapy is associated with a significantly increased risk of MACEs, hypertension, and thromboembolic events of any grade compared with controls. The lack of a significant increased risk of high-grade events together with the absolute low incidence of these adverse events led not to consider routine cardiovascular monitoring as recommended in asymptomatic patients.
Collapse
Affiliation(s)
- A Palazzo
- Medical Oncology Unit, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome
| | - C Ciccarese
- Medical Oncology Unit, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome
| | - R Iacovelli
- Medical Oncology Unit, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome; Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy.
| | - M C Cannizzaro
- Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - A Stefani
- Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - L Salvatore
- Medical Oncology Unit, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome; Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - E Bria
- Medical Oncology Unit, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome; Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - G Tortora
- Medical Oncology Unit, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome; Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
| |
Collapse
|
4
|
Zecchin M, Trevisan B, Bessi R, Baggio C, Salvatore L, Cappelletto C, Gregorio C, Bianco E, Carriere C, Longaro F, Zorzin-Fantasia A, Saitta M, Piccinin F, Dal Monte G, Sinagra G. Medium term survival in patients over ninety years-old undergoing pacemaker implantation. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
According to the Italian National Statistical Institute, the 12-month probability of survival in the general population between 90 and 94 years-old is 26%. Pacemaker (PM) implantation is often an urgent and necessary intervention, but in these patients the benefit in terms of quality and duration of life is unclear.
Purpose
To analyze characteristics, outcome and factors associated with survival in patients who had turned 90 at the time of PM implant.
Methods
All the PM implants performed in patients ≥90 from 1/1/2019 to 12/31/2020 were analyzed. Clinical parameters, device characteristics and follow-up data were extrapolated from the SuitEstensa Ebit reporting system; the exitus was verified by analyzing data from the Regional Health System.
Results
During the study interval, among the 554 patients undergoing PM implantation in our Center, 69 (12%) were ≥90 years-old (mean age 92±2 years, 46% male; complete/advanced AV block in 76%). Twenty-six (38%) patients had history of atrial fibrillation and 19 (28%) ischemic heart disease. A cardiological co-morbidity (excluding AF) was present in 23 patients (33%). Oncological, pneumological and neurological comorbidities were present in 12 (18%), 19 (28%) and 32 (46%) respectively. Renal impairment was present in 25 patients (36%). In 47 patients (68%) there were at least 2 co-morbidities. After implantation (single-chamber in 36, dual-chamber in 25 and VDD single-lead dual-chamber in 8 patients) complications occurred in 3 patients (2 pneumothorax and 1 lead dislodgment). Remote monitoring was activated in 57 patients (83%).
Within August 31st 2021 (mean follow-up 288±193 days) 24 patients died (35%, 219±241 days after implant). Five patients (19% of patients implanted in 2019) died within 12 months. No patients died for device malfunction. Three patients died because of COVID-19 pneumonia.
Renal dysfunction (Hazard Ratio-HR 8.05, p=0.002) and the presence of 2 or more co-morbidities (HR 6.03; p=0.015) were associated with a higher risk of death at univariate analysis; other significant variables were diabetes (HR 2.34; p=0.038), left ventricular ejection fraction (LVEF) (HR 0.70 for 5% variation; p=0.005), walking impairment (HR 2.99, p=0.006), the presence of oncological (HR 2.21; p=0.003), pneumological (HR 2.55; p=0.024) and neurological (HR 1.90, p=0.007) comorbidities. At multivariable analysis the only significant parameter associated with survival was LVEF (0.76 for 5% difference; p=0.043)
Conclusions
At our Center, patients ≥90 years-old undergo PM implantation mainly for advanced AVB. The good survival in the medium term, even better than expected in the general population, does not justify a too conservative attitude especially, but exclusively, in patients with less comorbidities.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- M Zecchin
- Cattinara Hospital , Trieste , Italy
| | | | - R Bessi
- Cattinara Hospital , Trieste , Italy
| | - C Baggio
- Cattinara Hospital , Trieste , Italy
| | | | | | | | - E Bianco
- Cattinara Hospital , Trieste , Italy
| | | | - F Longaro
- Cattinara Hospital , Trieste , Italy
| | | | - M Saitta
- Cattinara Hospital , Trieste , Italy
| | | | | | - G Sinagra
- Cattinara Hospital , Trieste , Italy
| |
Collapse
|
5
|
Milella M, Orsi G, Palloni A, Salvatore L, Procaccio L, Noventa S, Bozzarelli S, Garajova I, Vasile E, Giordano G, Macchini M, Cavaliere A, Gaule M, Lonardi S, Di Marco M, Tortora G, Sperduti I, Reni M. 1307P Real-world impact of olaparib use in advanced pancreatic cancer (PC) patients (pts) harboring germline BRCA1/2 (gBRCA) mutations. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
6
|
Gurreri E, Chiaravalli M, Bensi M, Bagalà C, Di Stefano B, Beccia V, Spring A, Monaca F, Barone D, Maratta M, Tortora G, Salvatore L. P-148 The impact of second-line treatment after fist-line cisplatin plus gemcitabine in advanced biliary tract cancers: A mono-institutional retrospective study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
7
|
Antoniotti C, Boccaccino A, Seitz R, Giordano M, Rossini D, Ambrosini M, Salvatore L, McGregor K, Bergamo F, Conca V, Leonetti S, Provenzano L, Tamberi S, Ramundo M, Tortora G, Rasola C, Ross D, Passardi A, Nielsen T, Varga M, Cremolini C. SO-36 An immune-related gene expression profile predicts the efficacy of adding atezolizumab to first-line FOLFOXIRI/bevacizumab in metastatic colorectal cancer: A translational analysis of the phase II randomized AtezoTRIBE study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
8
|
Bensi M, Ribelli M, Di Stefano B, Beccia V, Spring A, Gurreri E, Monaca F, Barone D, Chiaravalli M, Maratta M, Bagalà C, Tortora G, Salvatore L. P-97 DNA damage repair (DDR) germline mutations (GMs) in pancreatic ductal adenocarcinoma (PDAC): A mono-institutional retrospective study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
9
|
Cremolini C, Rossini D, Antoniotti C, Pietrantonio F, Lonardi S, Salvatore L, Marmorino F, Borelli B, Ambrosini M, Barsotti G, Di Stefano B, Masi G, Boccaccino A, Tamberi S, Tamburini E, Frassineti L, Simionato F, Fontanini G, Boni L, Falcone A. LBA20 FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.2094] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
10
|
Pietrantonio F, Morano F, Lonardi S, Raimondi A, Salvatore L, Marmorino F, Murgioni S, Pella N, Antonuzzo L, Ritorto G, Zaniboni A, Ratti M, Palermo F, Pagani F, Prisciandaro M, Cagnazzo C, Capone I, Milione M, Di Bartolomeo M, de Braud F. 383O MAYA trial: Temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.905] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
11
|
Hafliger E, Boccaccino A, El-Khoury R, Perret A, Pietrantonio F, Pilla L, Lecomte T, Scartozzi M, Soularue E, Salvatore L, Bourgeois V, Salati M, Vaillant J, Gallois C, Lonardi S, Cremolini C, Taieb J. 440P Response to BRAF inhibitors combined with anti-EGFR after previous anti-EGFR exposure for BRAF V600E mutant metastatic colorectal cancer patients. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.961] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
12
|
Salvatore L, Bensi M, Corallo S, Bergamo F, Pellegrini I, Rasola C, Borelli B, Tamburini E, Randon G, Galuppo S, Boccaccino A, Viola M, Auriemma A, Fea E, Barbara C, Corvari B, Bustreo S, Smiroldo V, Barbaro B, Tortora G. O-12 Phase II study of preoperative chemoradiotherapy plus avelumab in patients with locally advanced rectal cancer: The AVANA study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
13
|
Camarda F, Ardito F, Lococo F, Bensi M, Di Stefano B, Vellone M, Chiappetta M, Ribelli M, Anghelone A, Schietroma F, Valente G, Mele C, Tabacco D, Calegari M, Basso M, Pozzo C, Margaritora S, Giuliante F, Tortora G, Salvatore L. P-73 The role of site of metastatic resection in metastatic colorectal cancer patients: A mono-institutional cohort study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
14
|
Peretti U, Cavaliere A, Niger M, Tortora G, Di Marco MC, Rodriquenz MG, Centonze F, Rapposelli IG, Giordano G, De Vita F, Stuppia L, Avallone A, Ratti M, Paratore C, Forti LG, Orsi G, Valente MM, Gaule M, Macchini M, Carrera P, Calzavara S, Simbolo M, Melisi D, De Braud F, Salvatore L, De Lorenzo S, Chiarazzo C, Falconi M, Cascinu S, Milella M, Reni M. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. ESMO Open 2021; 6:100032. [PMID: 33399070 PMCID: PMC7807989 DOI: 10.1016/j.esmoop.2020.100032] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 11/26/2020] [Accepted: 11/27/2020] [Indexed: 02/08/2023] Open
Abstract
OBJECTIVE Germline BRCA1-2 pathogenic variants (gBRCApv) increase the risk of pancreatic cancer and predict for response to platinating agents and poly(ADP-ribose) polymerase inhibitors. Data on worldwide gBRCApv incidence among pancreatic ductal adenocarcinoma (PDAC) patients are sparse and describe a remarkable geographic heterogeneity. The aim of this study is to analyze the epidemiology of gBRCApv in Italian patients. MATERIALS AND METHODS Patients of any age with pancreatic adenocarcinoma, screened within 3 months from diagnosis for gBRCApv in Italian oncologic centers systematically performing tests without any selection. For the purposes of our analysis, breast, ovarian, pancreas, and prostate cancer in a patient's family history was considered as potentially BRCA-associated. Patients or disease characteristics were examined using the χ2 test or Fisher's exact test for qualitative variables and the Student's t-test or Mann-Whitney test for continuous variables, as appropriate. RESULTS Between June 2015 and May 2020, 939 patients were tested by 14 Italian centers; 492 (52%) males, median age 62 years (range 28-87), 569 (61%) metastatic, 273 (29%) with a family history of potentially BRCA-associated cancers. gBRCA1-2pv were found in 76 patients (8.1%; 9.1% in metastatic; 6.4% in non-metastatic). The gBRCA2/gBRCA1 ratio was 5.4 : 1. Patients with gBRCApv were younger compared with wild-type (59 versus 62 years, P = 0.01). The gBRCApv rate was 17.1% among patients <40 years old, 10.4% among patients 41-50 years old, 9.2% among patients 51-60 years old, 6.7% among patients aged 61-70 years, and 6.2% among patients >70 years old (none out of 94 patients >73 years old). gBRCApv frequency in 845 patients <74 years old was 9%. Patients with/without a family history of potentially BRCA-associated tumors had 14%/6% mutations. CONCLUSION Based on our findings of a gBRCApv incidence higher than expected in a real-life series of Italian patients with incident PDAC, we recommend screening all PDAC patients <74 years old, regardless of family history and stage, due to the therapeutic implications and cancer risk prevention in patients' relatives.
Collapse
Affiliation(s)
- U Peretti
- Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy; Pancreas Translational & Clinical Research Center, 'Vita-Salute' University, San Raffaele Scientific Institute, Milan, Italy
| | - A Cavaliere
- Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy
| | - M Niger
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - G Tortora
- Department of Medicine, Section of Medical Oncology, Fondazione Policlinico Universitario Gemelli IRCCS, Rome, Italy
| | - M C Di Marco
- Medical Oncology Division, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy; Medical Oncology Division, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - M G Rodriquenz
- Oncology Unit, foundation IRCCS Casa Sollievo della sofferenza, San Giovanni Rotondo, Foggia, Italy
| | - F Centonze
- Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy; Pancreas Translational & Clinical Research Center, 'Vita-Salute' University, San Raffaele Scientific Institute, Milan, Italy
| | - I G Rapposelli
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - G Giordano
- Department of Medical Oncology, Policlinico Riuniti, Azienda Ospedaliero Universitarià, Foggia, Italy
| | - F De Vita
- Division of Medical Oncology, Department of Precision Medicine, School of Medicine, 'Luigi Vanvitelli' University of Campania, Naples, Italy
| | - L Stuppia
- Medical Genetics, Department of Psychological, Health and Territorial Sciences Center for Advanced Sciences and Technology G. d'Annunzio University Chieti-Pescara Italy, Chieti, Italy
| | - A Avallone
- Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori- IRCCS-Fondazione G. Pascale, Naples, Italy
| | - M Ratti
- Department of Oncology, Medical Department, ASST di Cremona, Ospedale di Cremona, Cremona, Italy
| | - C Paratore
- Chiara Paratore, University of Turin, Ordine Mauriziano Hospital, Largo Filippo Turati, Turin, Italy
| | - L G Forti
- SCDU Oncologia, AOU Maggiore della Carità, Novara, Italy
| | - G Orsi
- Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy; Pancreas Translational & Clinical Research Center, 'Vita-Salute' University, San Raffaele Scientific Institute, Milan, Italy
| | - M M Valente
- Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy; Pancreas Translational & Clinical Research Center, 'Vita-Salute' University, San Raffaele Scientific Institute, Milan, Italy
| | - M Gaule
- Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy
| | - M Macchini
- Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy; Pancreas Translational & Clinical Research Center, 'Vita-Salute' University, San Raffaele Scientific Institute, Milan, Italy
| | - P Carrera
- Clinical Genomics - Molecular Genetics Service, Genomics for Diagnosis of Human Diseases, San Raffaele Hospital, Milan, Italy
| | - S Calzavara
- Clinical Genomics - Molecular Genetics Service, Genomics for Diagnosis of Human Diseases, San Raffaele Hospital, Milan, Italy
| | - M Simbolo
- Section of Pathology, Department of Diagnostics and Public Health, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy
| | - D Melisi
- Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy
| | - F De Braud
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
| | - L Salvatore
- Department of Medicine, Section of Medical Oncology, Fondazione Policlinico Universitario Gemelli IRCCS, Rome, Italy
| | - S De Lorenzo
- Medical Oncology Division, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - C Chiarazzo
- Oncology Unit, foundation IRCCS Casa Sollievo della sofferenza, San Giovanni Rotondo, Foggia, Italy
| | - M Falconi
- Pancreas Translational & Clinical Research Center, 'Vita-Salute' University, San Raffaele Scientific Institute, Milan, Italy; Department of Surgery, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - S Cascinu
- Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy; Pancreas Translational & Clinical Research Center, 'Vita-Salute' University, San Raffaele Scientific Institute, Milan, Italy
| | - M Milella
- Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy
| | - M Reni
- Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy; Pancreas Translational & Clinical Research Center, 'Vita-Salute' University, San Raffaele Scientific Institute, Milan, Italy.
| |
Collapse
|
15
|
Quero G, Salvatore L, Fiorillo C, Bagalà C, Menghi R, Maria B, Cina C, Laterza V, Di Stefano B, Maratta MG, Ribelli M, Galiandro F, Mattiucci GC, Brizi MG, Genco E, D'Aversa F, Zileri L, Attili F, Larghi A, Perri V, Inzani F, Gasbarrini A, Valentini V, Costamagna G, Manfredi R, Tortora G, Alfieri S. The impact of the multidisciplinary tumor board (MDTB) on the management of pancreatic diseases in a tertiary referral center. ESMO Open 2020; 6:100010. [PMID: 33399076 PMCID: PMC7910721 DOI: 10.1016/j.esmoop.2020.100010] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Revised: 11/06/2020] [Accepted: 11/10/2020] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND The implementation of multidisciplinary tumor board (MDTB) meetings significantly ameliorated the management of oncological diseases. However, few evidences are currently present on their impact on pancreatic cancer (PC) management. The aim of this study was to evaluate the impact of the MDTB on PC diagnosis, resectability and tumor response to oncological treatment compared with indications before discussion. PATIENTS AND METHODS All patients with a suspected or proven diagnosis of PC presented at the MDTB from 2017 to 2019 were included in the study. Changes of diagnosis, resectability and tumor response to oncological/radiation treatment between pre- and post-MDTB discussion were analyzed. RESULTS A total of 438 cases were included in the study: 249 (56.8%) were presented as new diagnoses, 148 (33.8%) for resectability assessment and 41 (9.4%) for tumor response evaluation to oncological treatment. MDTB discussion led to a change in diagnosis in 54/249 cases (21.7%), with a consequent treatment strategy variation in 36 cases (14.5%). Change in resectability was documented in 44/148 cases (29.7%), with the highest discrepancy for borderline lesions. The treatment strategy was thus modified in 27 patients (18.2%). The MDTB brought a modification in the tumor response assessment in 6/41 cases (14.6%), with a consequent protocol modification in four (9.8%) cases. CONCLUSIONS MDTB discussion significantly impacts on PC management, especially in high-volume centers, with consistent variations in terms of diagnosis, resectability and tumor response assessment compared with indications before discussion.
Collapse
Affiliation(s)
- G Quero
- Digestive Surgery Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; CRMPG (Advanced Pancreatic Research Center), Rome, Italy; Università Cattolica del Sacro Cuore di Roma, Rome, Italy.
| | - L Salvatore
- Università Cattolica del Sacro Cuore di Roma, Rome, Italy; Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
| | - C Fiorillo
- Digestive Surgery Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; CRMPG (Advanced Pancreatic Research Center), Rome, Italy
| | - C Bagalà
- Università Cattolica del Sacro Cuore di Roma, Rome, Italy; Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
| | - R Menghi
- Digestive Surgery Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; CRMPG (Advanced Pancreatic Research Center), Rome, Italy
| | - B Maria
- Università Cattolica del Sacro Cuore di Roma, Rome, Italy; Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
| | - C Cina
- Digestive Surgery Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; CRMPG (Advanced Pancreatic Research Center), Rome, Italy
| | - V Laterza
- Digestive Surgery Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; CRMPG (Advanced Pancreatic Research Center), Rome, Italy
| | - B Di Stefano
- Università Cattolica del Sacro Cuore di Roma, Rome, Italy; Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
| | - M G Maratta
- Università Cattolica del Sacro Cuore di Roma, Rome, Italy; Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
| | - M Ribelli
- Università Cattolica del Sacro Cuore di Roma, Rome, Italy; Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
| | - F Galiandro
- Digestive Surgery Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; CRMPG (Advanced Pancreatic Research Center), Rome, Italy
| | - G C Mattiucci
- Università Cattolica del Sacro Cuore di Roma, Rome, Italy; Radiation Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
| | - M G Brizi
- Università Cattolica del Sacro Cuore di Roma, Rome, Italy; Radiology Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
| | - E Genco
- Radiology Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
| | - F D'Aversa
- Internal Medicine, Gastroenterology and Hepatology Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
| | - L Zileri
- Internal Medicine, Gastroenterology and Hepatology Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
| | - F Attili
- Digestive Endoscopy Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; CERTT, Center for Endoscopic Research Therapeutics and Training, Università Cattolica del Sacro Cuore di Roma, Rome, Italy
| | - A Larghi
- Digestive Endoscopy Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; CERTT, Center for Endoscopic Research Therapeutics and Training, Università Cattolica del Sacro Cuore di Roma, Rome, Italy
| | - V Perri
- Digestive Endoscopy Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; CERTT, Center for Endoscopic Research Therapeutics and Training, Università Cattolica del Sacro Cuore di Roma, Rome, Italy
| | - F Inzani
- Pathology Unit, Università Cattolica del Sacro Cuore di Roma, Rome, Italy
| | - A Gasbarrini
- Università Cattolica del Sacro Cuore di Roma, Rome, Italy; Internal Medicine, Gastroenterology and Hepatology Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
| | - V Valentini
- Università Cattolica del Sacro Cuore di Roma, Rome, Italy; Radiation Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
| | - G Costamagna
- Università Cattolica del Sacro Cuore di Roma, Rome, Italy; Digestive Endoscopy Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; CERTT, Center for Endoscopic Research Therapeutics and Training, Università Cattolica del Sacro Cuore di Roma, Rome, Italy
| | - R Manfredi
- Università Cattolica del Sacro Cuore di Roma, Rome, Italy; Radiology Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
| | - G Tortora
- Università Cattolica del Sacro Cuore di Roma, Rome, Italy; Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
| | - S Alfieri
- Digestive Surgery Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; CRMPG (Advanced Pancreatic Research Center), Rome, Italy; Università Cattolica del Sacro Cuore di Roma, Rome, Italy
| |
Collapse
|
16
|
Anghelone A, Vivolo R, Boldrini L, Lenkowicz J, Caliolo G, Camarda F, Di Stefano B, Calegari M, Pozzo C, Basso M, Liguori C, Gaetano AD, Dinapoli N, Manfredi R, Valentini V, Tortora G, Salvatore L. P-166 Baseline radiomics features in metastatic colorectal cancer: Correlation with metastatic site and clinical-pathological characteristics. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
17
|
Stefano BD, Quero G, Bagalà C, Claudio F, Bensi M, Menghi R, Cina C, Mattiucci G, Manfredi R, Cellini F, Brizi M, D'Aversa F, Perri V, Larghi A, Attili F, Inzani F, Alfieri S, Tortora G, Salvatore L. P-102 The impact of a multidisciplinary approach in the management of pancreatic disease. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
18
|
Vivolo R, Bria E, Zurlo I, Bensi M, Dell'Aquila E, Anghelone A, Corsi D, Caira G, Santini D, Ingrosso D, Emiliani A, Calegari M, Citarella F, Pozzo C, Grande R, Basso M, Tortora G, Salvatore L. P-161 Efficacy of third-line anti-EGFR-based treatment versus regorafenib/TAS-102 (R/T) according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
19
|
Chiaravalli M, Bensi M, Stefano BD, Bagalà C, Spring A, Ribelli M, Maratta M, Tortora G, Salvatore L. P-164 The role of response as a predictor of improved outcome in advanced pancreatic cancer patients treated with first-line gemcitabine plus nab-paclitaxel. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
20
|
Camarda F, Ardito F, Bensi M, Vellone M, Stefano BD, Vivolo R, Mele C, Ribelli M, Panettieri E, Frascarelli A, Calegari M, Basso M, Pozzo C, Giuliante F, Tortora G, Salvatore L. P-103 The role of primary tumor site as a prognostic factor after resection of colorectal liver metastases: A mono-institutional cohort study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
21
|
Gallo L, Madaghiele M, Salvatore L, Barca A, Scialla S, Bettini S, Valli L, Verri T, Bucalá V, Sannino A. Integration of PLGA Microparticles in Collagen-Based Matrices: Tunable Scaffold Properties and Interaction Between Microparticles and Human Epithelial-Like Cells. INT J POLYM MATER PO 2020. [DOI: 10.1080/00914037.2018.1552857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- L.C. Gallo
- Department of Biology, Biochemistry and Pharmacy, Universidad Nacional del Sur, Bahía Blanca, Argentina
- Pilot Plant of Chemical Engineering, PLAPIQUI (UNS-CONICET), Bahía Blanca, Argentina
| | - M. Madaghiele
- Department of Engineering for Innovation, University of Salento, Lecce, Italy
| | - L. Salvatore
- Department of Engineering for Innovation, University of Salento, Lecce, Italy
| | - A. Barca
- Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy
| | - S. Scialla
- Department of Engineering for Innovation, University of Salento, Lecce, Italy
| | - S. Bettini
- Department of Engineering for Innovation, University of Salento, Lecce, Italy
| | - L. Valli
- Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy
| | - T. Verri
- Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy
| | - V. Bucalá
- Pilot Plant of Chemical Engineering, PLAPIQUI (UNS-CONICET), Bahía Blanca, Argentina
- Department of Chemical Engineering, Universidad Nacional del Sur, Bahía Blanca, Argentina
| | - A. Sannino
- Department of Engineering for Innovation, University of Salento, Lecce, Italy
| |
Collapse
|
22
|
Salvatore L, Bensi M, Pietrantonio F, Boccaccino A, Barbara C, Auriemma A, Ratti M, Tamburini E, Bordonaro R, Clavarezza M, Avallone A, Bergamo F, Granetto C, Bustreo S, Fabio FD, Smiroldo V, Corvari B, Tortora G. Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA Study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz246.139] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
23
|
Bensi M, Calegari M, Basso M, Orlandi A, Boccaccino A, Lombardo F, Zurlo I, Stefano BD, Camarda F, Vivolo R, Cocomazzi A, Martini M, Auriemma A, Pozzo C, Bria E, Salvatore L, Tortora G. Clinical, pathological, and prognostic features of rare BRAF mutations in metastatic colorectal cancer: a bi-institutional retrospective analysis (REBUS study). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Calegari M, Zurlo I, Basso M, Orlandi A, Bensi M, Camarda F, Stefano BD, Vivolo R, Pozzo C, Sperduti I, Bria E, Salvatore L, Tortora G. Chemotherapy rechallenge or reintroduction, regorafenib, and TAS-102 for metastatic pretreated colorectal cancer patients: a propensity score analysis of treatment beyond the second line (PROSERpINA Study). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.138] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
25
|
Salvatore L, Mattiucci G, Bensi M, Stefano BD, Cellini F, Bagalà C, Zurlo I, Reina S, Masiello V, De Franco P, Quero G, Giuliante F, Alfieri S, Valentini V, Tortora G. Role of chemoradiation (CRT) in the adjuvant treatment of radically resected pancreatic cancer (PC) patients (pts): a mono-institutional retrospective analysis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Rossini D, Pagani F, Pellino A, Dell’Aquila E, Liscia N, Bensi M, Germani M, Masi G, Moretto R, Santini D, Salvatore L, Scartozzi M, Lonardi S, Zucchelli G, Puglisi F, Vannini F, Colombo C, Falcone A, Pietrantonio F, Cremolini C. Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz156.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Salvatore L, Bria E, Sperduti I, Hinke A, Hegewisch-Becker S, Aparicio T, Le Malicot K, Boige V, Koeberle D, Baertschi D, Dietrich D, Tortora G, Arnold D. Bevacizumab (BV) maintenance after first-line chemotherapy plus BV for metastatic colorectal cancer patients: a meta-analysis of individual patients data from 3 phase III studies. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz156.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Kolpakov V, D'Adamo MC, Salvatore L, Amore C, Mironov A, lacoviello L, Donati MB. Neutrophil Derived Cathepsin G Induces Potentially Thrombogenic Changes in Human Endothelial Cells: a Scanning Electron Microscopy Study in Static and Dynamic Conditions. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1648825] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryActivated neutrophils may promote thrombus formation by releasing proteases which may activate platelets, impair the fibrinolytic balance and injure the endothelial monolayer.We have investigated the morphological correlates of damage induced by activated neutrophils on the vascular wall, in particular the vascular injury induced by released cathepsin G in both static and dynamic conditions.Human umbilical vein endothelial cells were studied both in a cell culture system and in a model of perfused umbilical veins. At scanning electron microscopy, progressive alterations of the cell monolayer resulted in cell contraction, disruption of the intercellular contacts, formation of gaps and cell detachment.Contraction was associated with shape change of the endothelial cells, that appeared star-like, while the underlying extracellular matrix, a potentially thrombogenic surface, was exposed. Comparable cellular response was observed in an “in vivo” model of perfused rat arterial segment. Interestingly, cathepsin G was active at lower concentrations in perfused vessels than in culture systems. Restoration of blood flow in the arterial segment previously damaged by cathepsin G caused adhesion and spreading of platelets on the surface of the exposed extracellular matrix. The subsequent deposition of a fibrin network among adherent platelets, could be at least partially ascribed to the inhibition by cathepsin G of the vascular fibrinolytic potential.This study supports the suggestion that the release of cathepsin G by activated neutrophils, f.i. during inflammation, may contribute to thrombus formation by inducing extensive vascular damage.
Collapse
Affiliation(s)
- Valeri Kolpakov
- The Laboratory of Thrombosis Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
| | - Maria Cristina D'Adamo
- The Laboratory of Thrombosis Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
| | - Lorena Salvatore
- The Laboratory of Thrombosis Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
| | - Concetta Amore
- The Laboratory of Thrombosis Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
| | | | - Licia lacoviello
- The Laboratory of Thrombosis Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
| | - Maria Benedetta Donati
- The Laboratory of Thrombosis Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
| |
Collapse
|
29
|
Marmorino F, Cremolini C, Bergamo F, Pella N, Antoniotti C, Rossini D, Dell'Aquila E, Masi G, Salvatore L, Loupakis F, Marcucci L, Gemma D, Cardellino G, Borelli B, Ricci V, Delfanti S, Mori E, Tonini G, Lonardi S, Fontanini G, Boni L, Falcone A. FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy149.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Benedetti M, De Caterina R, Bionda A, Gardinali M, Cicardi M, Maffei S, Gazzetti P, Pistolesi P, Vernazza F, Michelassi C, Giordani R, Salvatore L. Blood - Artificial Surface Interactions during Cardiopulmonary Bypass. Int J Artif Organs 2018. [DOI: 10.1177/039139889001300808] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Evaluation of the biocompatibility of four different types of oxygenator (bubble, membrane, hollow fibre and ‘hybrid’) was performed on 26 patients undergoing cardiopulmonary bypass during elective coronary surgery. More platelet derangement and an increased degree of hemolysis, revealed by higher plasmatic concentration of beta-thromboglobulin, platelet factor 4 and plasmatic free hemoglobin (p < 0.05), was seen when using the bubble oxygenator. Damage to blood cells was minimal with the membrane oxygenator while the ‘hybrid’ and the hollow fibre oxygenators proved to rank at an intermediate level. Complement activation at the beginning of the cardiopulmonary bypass occurred via the alternative pathway as demonstrated by C3adesarg increase (up to nine times) without a concomitant elevation of C4adesarg. Cardiopulmonary bypass complement activation was quantitatively similar with all the oxygenators. A further activation via the classical pathway occured in all the patients after protamine injection. Consistent differences as far as clinical and biological effects exist among the various commercially available cardiopulmonary bypass apparatus; our study provides guidelines for the evaluation and selection of devices which might reduce postoperative sequelae.
Collapse
Affiliation(s)
| | | | - A. Bionda
- II Medical Clinic, University of Pisa, Pisa, Milano - Italy
| | - M. Gardinali
- V Medical Clinic, University of Milano, Milano - Italy
| | - M. Cicardi
- V Medical Clinic, University of Milano, Milano - Italy
| | - S. Maffei
- Department of Cardiac Surgery, Milano - Italy
| | - P. Gazzetti
- CNR Institute of Clinical Physiology, Milano - Italy
| | - P. Pistolesi
- II Medical Clinic, University of Pisa, Pisa, Milano - Italy
| | - F. Vernazza
- Department of Cardiac Surgery, Milano - Italy
| | - C. Michelassi
- CNR Institute of Clinical Physiology, Milano - Italy
| | - R. Giordani
- II Medical Clinic, University of Pisa, Pisa, Milano - Italy
| | | |
Collapse
|
31
|
Terzi A, Storelli E, Bettini S, Sibillano T, Altamura D, Salvatore L, Madaghiele M, Romano A, Siliqi D, Ladisa M, De Caro L, Quattrini A, Valli L, Sannino A, Giannini C. Effects of processing on structural, mechanical and biological properties of collagen-based substrates for regenerative medicine. Sci Rep 2018; 8:1429. [PMID: 29362434 PMCID: PMC5780384 DOI: 10.1038/s41598-018-19786-0] [Citation(s) in RCA: 69] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2017] [Accepted: 12/11/2017] [Indexed: 12/21/2022] Open
Abstract
The aim of this work was to investigate the structural features of type I collagen isoforms and collagen-based films at atomic and molecular scales, in order to evaluate whether and to what extent different protocols of slurry synthesis may change the protein structure and the final properties of the developed scaffolds. Wide Angle X-ray Scattering data on raw materials demonstrated the preferential orientation of collagen molecules in equine tendon-derived collagens, while randomly oriented molecules were found in bovine skin collagens, together with a lower crystalline degree, analyzed by the assessment of FWHM (Full Width at Half Maximum), and a certain degree of salt contamination. WAXS and FT-IR (Fourier Transform Infrared) analyses on bovine collagen-based films, showed that mechanical homogenization of slurry in acidic solution was the treatment ensuring a high content of super-organization of collagen into triple helices and a high crystalline domain into the material. In vitro tests on rat Schwannoma cells showed that Schwann cell differentiation into myelinating cells was dependent on the specific collagen film being used, and was found to be stimulated in case of homogenization-treated samples. Finally DHT/EDC crosslinking treatment was shown to affect mechanical stiffness of films depending on collagen source and processing conditions.
Collapse
Affiliation(s)
- A Terzi
- Institute of Crystallography (IC), National Research Council, Bari, Italy
| | - E Storelli
- Department of Engineering for Innovation, University of Salento, Lecce, Italy
- Neuropathology Unit, Institute of Experimental Neurology and Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - S Bettini
- Department of Engineering for Innovation, University of Salento, Lecce, Italy
| | - T Sibillano
- Institute of Crystallography (IC), National Research Council, Bari, Italy
| | - D Altamura
- Institute of Crystallography (IC), National Research Council, Bari, Italy
| | - L Salvatore
- Department of Engineering for Innovation, University of Salento, Lecce, Italy
| | - M Madaghiele
- Department of Engineering for Innovation, University of Salento, Lecce, Italy
| | - A Romano
- Neuropathology Unit, Institute of Experimental Neurology and Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - D Siliqi
- Institute of Crystallography (IC), National Research Council, Bari, Italy
| | - M Ladisa
- Institute of Crystallography (IC), National Research Council, Bari, Italy
| | - L De Caro
- Institute of Crystallography (IC), National Research Council, Bari, Italy
| | - A Quattrini
- Neuropathology Unit, Institute of Experimental Neurology and Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - L Valli
- Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy
| | - A Sannino
- Department of Engineering for Innovation, University of Salento, Lecce, Italy
| | - C Giannini
- Institute of Crystallography (IC), National Research Council, Bari, Italy.
| |
Collapse
|
32
|
Di Giancamillo A, Deponti D, Gervaso F, Salvatore L, Scalera F, Mangiavini L, Scurati R, Sannino A, Peretti GM. The analysis of different scaffolds and the benefit of fibrin glue for tendon tissue engineering at different culture times. J BIOL REG HOMEOS AG 2017; 31:67-73. [PMID: 29185298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
This study evaluated a tendon substitute model. Tenocytes were isolated from pig Achilles tendon, seeded onto scaffolds (Opocrin 2%, Typeone 3% and Symatese 2%) and studied by histology, immunofluorescence for collagen type 1 and 3 and biochemical analysis to assess cellularity. The permeability of these compounds was evaluated in the presence or absence of fibrin glue. Opocrin 2% was the best choice for cellular distribution within the scaffolds, which were then cultured for T0, T4, T7 and T10 days. Fibrin glue has been strongly supportive for the survival of cells with a significant increase in DNA content at T10 (P<0.05). Moreover, the synthetic activity of fibrin-free scaffolds was always negative. Lastly, a progressive increase in collagen 1 and 3 with fibrin-glue was observed. However, static culture is not sufficient to support long-term cellular activities and at T10 there is still a lack of organized matrix similar to the native tissue.
Collapse
Affiliation(s)
- A Di Giancamillo
- Department of Health, Animal Science and Food Safety, University of Milan, Italy
| | - D Deponti
- IRCCS, Ospedale San Raffaele, Milan, Italy
| | - F Gervaso
- Department of Engineering for Innovation, University of Salento, Italy
| | - L Salvatore
- Department of Engineering for Innovation, University of Salento, Italy
| | - F Scalera
- Department of Engineering for Innovation, University of Salento, Italy
| | - L Mangiavini
- IRCCS Istituto Ortopedico Galeazzi, Milan, Italy
| | - R Scurati
- Department of Biomedical Sciences for Health, University of Milan, Italy
| | - A Sannino
- Department of Engineering for Innovation, University of Salento, Italy
| | - G M Peretti
- IRCCS Istituto Ortopedico Galeazzi, Milan, Italy
- Department of Biomedical Sciences for Health, University of Milan, Italy
| |
Collapse
|
33
|
Trestini I, Carbognin L, Bonaiuto C, Auriemma A, Melisi D, Salvatore L, Sperduti I, Bria E, Tortora G. Prognostic impact of nutritional support in patients affected by locally advanced or metastatic pancreatic cancer (PC) undergone chemotherapy. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx425.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Santini D, Cremolini C, Salvatore L, Lonardi S, Dell'Aquila E, Cattaneo M, Loupakis F, Rossini D, Vincenzi B, Ziampiri S, Buoro V, Tamburini E, Basile D, Corsi D, Fioroni I, Masi G, Borelli B, Del Re M, Tonini G, Falcone A. Rechallenge with cetuximab (cet) + irinotecan (iri) in 3rd-line in RAS and BRAF wt metastatic colorectal cancer (mCRC) patients (pts) with acquired resistance to 1st-line cet + iri: the phase II CRICKET study by GONO. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx422.019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
35
|
Bettini S, Giancane G, Pagano R, Bonfrate V, Salvatore L, Madaghiele M, Buccolieri A, Manno D, Serra A, Maruccio G, Monteduro AG, Syrgiannis Z, Valli L, Prato M. A simple approach to synthetize folic acid decorated magnetite@SiO2 nanostructures for hyperthermia applications. J Mater Chem B 2017; 5:7547-7556. [DOI: 10.1039/c7tb02002c] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Folic Acid decorated SPIONs selective internalization was monitored by an innovative Ellipsometry imaging approach.
Collapse
|
36
|
Okazaki S, Loupakis F, Schirripa M, Cao S, Zhang W, Yang D, Ning Y, Berger M, Miyamoto Y, Suenaga M, Gopez R, Borelli B, Cremolini C, Falcone A, Lonardi S, Salvatore L, Uetake H, Kawano T, Helentjaris T, Lenz HJ. Tandem repeat variation in HIC1 gene predicts outcome for oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw363.72] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
Falcone A, Cremolini C, Loupakis F, Lonardi S, Casagrande M, Murgioni S, Salvatore L, Masi G, Fanotto V, Granetto C, Marmorino F, Ginocchi L, Ziampiri S, Grande R, Tonini G, Delfanti S, Di Donato S, Fontanini G, Boni L, Zagonel V. FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw435.13] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
38
|
Salvatore L, Niger M, Bellu L, Tamburini E, Garcia-Alfonso P, Amellal N, Delmas AS, Wahba M, Prager G. Compassionate use program for trifluridine/tipiracil (TAS-102) in metastatic colorectal cancer: a real-life overview. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.60] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Marmorino F, Cremolini C, Loupakis F, Salvatore L, Masi G, Barbara C, Dargenio F, Miraglio E, Ginocchi L, Antonuzzo L, Moretto R, Schirripa M, Chiara S, Banzi C, Amoroso D, Bonetti A, Martignetti A, Paris M, Boni L, Tomcikova D, Falcone A. Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
40
|
Casagrande M, Cremolini C, Zucchelli G, Bergamo F, Ferrari L, Pietrantonio F, Lonardi S, Loupakis F, Masi G, Pella N, Intini R, Salvatore L, Tomasello G, Pagani F, Pellino A, Dell'Aquila E, Ginocchi L, Milione M, Fea E, Pellegrinelli A, Falcone A. FOLFOXIRI plus bevacizumab (bev) as upfront treatment for metastatic colorectal cancer (mCRC) patients (pts) with initially unresectable liver-limited disease (LLD). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
41
|
Ciardiello F, Salvatore L, Cascinu S, Sobrero A, Banzi C, Barone C, Spallanzani A, Latiano T, Siena S, Bergamo F, Cartenì G, Di Costanzo F, Di Bartolomeo M, Santoro A, Russo A, Russo A, Moscovici M, Van Cutsem E, Grothey A, Zaniboni A. Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase 3b CONSIGN trial. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Salvatore L, Ciardiello F, Cascinu S, Sobrero A, Banzi C, Barone C, Gelsomino F, Maiello E, Siena S, Bergamo F, Cartenì G, Di Costanzo F, Di Bartolomeo M, Rimassa L, Russo A, Moscovici M, Van Cutsem E, Grothey A, Zaniboni A. Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) >4 months (m). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.27] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Antoniotti C, Cremolini C, Loupakis F, Bergamo F, Grande R, Tonini G, Garattini Silvio K, Masi G, Battaglin F, Lucchesi S, Salvatore L, Corsi D, Di Fabio F, Banzi M, Moretto R, Sensi E, Rossini D, Tomcikova D, Fontanini G, Zagonel V, Boni L, Falcone A. O-011 Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw198.11] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
Casagrande M, Moretto R, Loupakis F, Cremolini C, Masi G, Borelli B, Lonardi S, Marsico Valentina A, Salvatore L, Rossini D, Ferrari L, Ricci V, Grande R, Tomasello G, Ronzoni M, Allegrini G, Tonini G, Mancini M, Zaniboni A, Chiara S, Carlomagno C, Falcone A. PD-009 Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: a pooled analysis of GONO studies. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw200.09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Marmorino F, Cremolini C, Loupakis F, Antoniotti C, Barbara C, Dargenio F, Miraglio E, Masi G, Salvatore L, Schirripa M, Borelli B, Marcucci L, Antonuzzo L, Chiara S, Banzi C, Amoroso D, Bonetti A, Martignetti A, Paris M, Boni L, Tomcikova D, Falcone A. PD-004 Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw200.04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
46
|
Vacca M, Di Eusanio M, Cariello M, Graziano G, D'Amore S, Petridis FD, D'orazio A, Salvatore L, Tamburro A, Folesani G, Rutigliano D, Pellegrini F, Sabbà C, Palasciano G, Di Bartolomeo R, Moschetta A. Integrative miRNA and whole-genome analyses of epicardial adipose tissue in patients with coronary atherosclerosis. Cardiovasc Res 2015; 109:228-39. [PMID: 26645979 DOI: 10.1093/cvr/cvv266] [Citation(s) in RCA: 72] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/01/2015] [Accepted: 11/14/2015] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Epicardial adipose tissue (EAT) is an atypical fat depot surrounding the heart with a putative role in the development of atherosclerosis. METHODS AND RESULTS We profiled genes and miRNAs in perivascular EAT and subcutaneous adipose tissue (SAT) of metabolically healthy patients without coronary artery disease (CAD) vs. metabolic patients with CAD. Compared with SAT, a specific tuning of miRNAs and genes points to EAT as a tissue characterized by a metabolically active and pro-inflammatory profile. Then, we depicted both miRNA and gene signatures of EAT in CAD, featuring a down-regulation of genes involved in lipid metabolism, mitochondrial function, nuclear receptor transcriptional activity, and an up-regulation of those involved in antigen presentation, chemokine signalling, and inflammation. Finally, we identified miR-103-3p as candidate modulator of CCL13 in EAT, and a potential biomarker role for the chemokine CCL13 in CAD. CONCLUSION EAT in CAD is characterized by changes in the regulation of metabolism and inflammation with miR-103-3p/CCL13 pair as novel putative actors in EAT function and CAD.
Collapse
Affiliation(s)
- Michele Vacca
- Department of Interdisciplinary Medicine, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124 Bari, Italy Fondazione Mario Negri Sud, Santa Maria Imbaro (CH), Italy Ageing Research Center (CeSI), 'G. d'Annunzio' University Foundation, Chieti, Italy
| | - Marco Di Eusanio
- Cardiovascular Department, 'S.Orsola Malpighi' Hospital, University of Bologna, Bologna, Italy
| | - Marica Cariello
- Department of Interdisciplinary Medicine, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124 Bari, Italy National Cancer Research Center IRCCS 'Giovanni Paolo II', Bari, Italy
| | - Giusi Graziano
- Department of Interdisciplinary Medicine, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124 Bari, Italy National Cancer Research Center IRCCS 'Giovanni Paolo II', Bari, Italy
| | - Simona D'Amore
- Department of Interdisciplinary Medicine, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124 Bari, Italy Fondazione Mario Negri Sud, Santa Maria Imbaro (CH), Italy National Cancer Research Center IRCCS 'Giovanni Paolo II', Bari, Italy
| | | | | | | | | | - Gianluca Folesani
- Cardiovascular Department, 'S.Orsola Malpighi' Hospital, University of Bologna, Bologna, Italy
| | | | | | - Carlo Sabbà
- Department of Interdisciplinary Medicine, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Giuseppe Palasciano
- Department of Interdisciplinary Medicine, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Roberto Di Bartolomeo
- Cardiovascular Department, 'S.Orsola Malpighi' Hospital, University of Bologna, Bologna, Italy
| | - Antonio Moschetta
- Department of Interdisciplinary Medicine, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124 Bari, Italy Fondazione Mario Negri Sud, Santa Maria Imbaro (CH), Italy National Cancer Research Center IRCCS 'Giovanni Paolo II', Bari, Italy
| |
Collapse
|
47
|
Antoniotti C, Loupakis F, Schirripa M, Cremolini C, Poliseno L, Salvatore L, Tuccoli A, D'Aurizio R, Marmorino F, Borelli B, Rossini D, Saettini A, Gini S, Moretto R, Rizzo I, Dell'Aquila E, Pellegrini M, Falcone A. Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv340.06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Rihawi K, Fontanella C, Rossini D, Schirripa M, De Carlo E, Salvatore L, Ongaro E, Casagrande M, Ferrari L, Pella N, Cardellino G, Giovannoni M, Iaiza E, Ermacora P, Puglisi F, Loupakis F, Falcone A, Pisa F, Aprile G, Fasola G. KRAS status and risk of venous thromboembolic events in patients with metastatic colorectal cancer: a case-control study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv340.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
49
|
Falcone A, Cremolini C, Antoniotti C, Lonardi S, Ronzoni M, Zaniboni A, Tonini G, Salvatore L, Masi G, Mezi S, Tomasello G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Lupi C, Sensi E, Fontanini G, Boni L, Loupakis F. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): updated survival results and final molecular subgroups analyses. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv335.02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
50
|
Ciardiello F, Salvatore L, Cascinu S, Sobrero A, Banzi M, Barone C, Spallanzani A, Latiano T, Amatu A, Zagonel V, Biglietto M, Di Costanzo F, Di Bartolomeo M, Santoro A, Russo A, Moscovici M, Van Cutsem E, Zaniboni A. Regorafenib for previously treated metastatic colorectal cancer (mCRC): results from 683 Italian patients treated in the open-label phase IIIB CONSIGN study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv340.04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|